The natural history of progressive fibrosing interstitial lung diseases
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
We used data from the INBUILD and INPULSIS trials to investigate the natural history of progressive fibrosing interstitial lung diseases (ILDs). Subjects in the two INPULSIS trials had a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) while subjects in the INBUILD trial had a progressive fibrosing ILD other than IPF and met protocol-defined criteria for ILD progression despite management. Using data from the placebo groups, we compared the rate of decline in forced vital capacity (FVC) (mL·year −1 ) and mortality over 52 weeks in the INBUILD trial with pooled data from the INPULSIS trials. The adjusted mean annual rate of decline in FVC in the INBUILD trial (n=331) was similar to that observed in the INPULSIS trials (n=423) (−192.9 mL·year −1 and −221.0 mL·year −1 , respectively; nominal p-value=0.19). The proportion of subjects who had a relative decline in FVC >10% predicted at Week 52 was 48.9% in the INBUILD trial and 48.7% in the INPULSIS trials, and the proportion who died over 52 weeks was 5.1% in the INBUILD trial and 7.8% in the INPULSIS trials. A relative decline in FVC >10% predicted was associated with an increased risk of death in the INBUILD trial (hazard ratio 3.64) and the INPULSIS trials (hazard ratio 3.95). These findings indicate that patients with fibrosing ILDs other than IPF, who are progressing despite management, have a subsequent clinical course similar to patients with untreated IPF, with a high risk of further ILD progression and early mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At this point, no biomarker or clinical prediction algorithm has been established as a reliable predictor for disease outcome or response to therapy in ILD.(233)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [233]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationNintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib is an intracellular inhibitor of tyrosine kinases [10, 25].”
BackgroundMechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationUsual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Kim, E. J., Elicker, B. M., Maldonado, F., Webb, W. R., Ryu, J. H., Van Uden, J. H., Lee, J. S., King, T. E., & Collard, H. R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00092309 · Cited by 587 · cited 2×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
BackgroundWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527 · cited 1×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citationPredictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388 · cited 2×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citation
Cited by
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
“Therefore, the committee derived the physiological criteria for PPF by extrapolation of data from patients with IPF because the disease behavior and prognosis of IPF and PPF are comparable (124).”
MethodLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Pulmonary fibrosis secondary to COVID-19: a call to arms?
Spagnolo, P., Balestro, E., Aliberti, S., Cocconcelli, E., Biondini, D., Casa, G. D., Sverzellati, N., & Maher, T. M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30222-8 · Cited by 481
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503643 · Cited by 205
Self-citationHambly, N., Farooqi, M. M., Dvorkin-Gheva, A., Donohoe, K., Garlick, K., Scallan, C., Chong, S. G., MacIsaac, S., Assayag, D., Johannson, K. A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02571-2021 · Cited by 186
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01487-0 · Cited by 161
Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review
Gupta, R. S., Koteci, A., Morgan, A. D., George, P. M., & Quint, J. K. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001291 · Cited by 174
Diagnosis, course and management of hypersensitivity pneumonitis
Hamblin, M., Prosch, H., & Vašáková, M. (2022) · European Respiratory Review · doi:10.1183/16000617.0169-2021 · Cited by 169
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Inoue, Y., Richeldi, L., Walsh, S. L. F., Kolb, M. R. J., Koschel, D., Moua, T., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04538-2020 · Cited by 150
Self-citationWalsh, S. L. F., Mackintosh, J. A., Calandriello, L., Silva, M., Sverzellati, N., Larici, A. R., Humphries, S. M., Lynch, D. A., Jo, H. E., Glaspole, I., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2684oc · Cited by 145
Self-citationMatteson, E. L., Kelly, C. A., Distler, J. H. W., Hoffmann‐Vold, A., Seibold, J. R., Mittoo, S., Dellaripa, P. F., Aringer, M., Pope, J. E., Distler, O., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42075 · Cited by 138
Self-citationSelman, M., & Pardo, A. (2021) · European Respiratory Journal · doi:10.1183/13993003.04507-2020 · Cited by 88
Matteson, E. L., Aringer, M., Burmester, G. R., Mueller, H., Moros, L., & Kolb, M. R. J. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06623-7 · Cited by 95
Irreversibility of Pulmonary Fibrosis
Yu, Q. Y., & Tang, X. X. (2022) · Aging and Disease · doi:10.14336/ad.2021.0730 · Cited by 89
Nasser, M., Larrieu, S., Boussel, L., Si-Mohamed, S. A., Bazin, F., Marque, S., Massol, J., Thivolet-Béjui, F., Chalabreysse, L., Maucort‐Boulch, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01749-1 · Cited by 90
Self-citationThe burden of progressive fibrotic interstitial lung disease across the UK
Simpson, T., Barratt, S. L., Beirne, P., Chaudhuri, N., Crawshaw, A., Crowley, L., Fletcher, S., Gibbons, M., Hallchurch, P., Horgan, L., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00221-2021 · Cited by 81
Cooley, J. C., Javkhlan, N., Wilson, J. A., Foster, D. G., Edelman, B., Ortiz, L. A., Schwartz, D. A., Riches, D. W. H., & Redente, E. F. (2023) · JCI Insight · doi:10.1172/jci.insight.163762 · Cited by 83
“coidosis, and nonspecific interstitial pneumonia (1).”
BackgroundTrachalaki, A., Tsitoura, E., Mastrodimou, S., Invernizzi, R., Vasarmidi, E., Bibaki, E., Tzanakis, Ν., Molyneaux, P. L., Maher, T. M., & Antoniou, K. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661811 · Cited by 85
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Kwon, B. S., Choe, J., Chae, E. J., Hwang, H. S., Kim, Y., & Song, J. W. (2021) · Respiratory Research · doi:10.1186/s12931-021-01879-6 · Cited by 79
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Cottin, V., Richeldi, L., Rosas, I. O., Otaola, M., Song, J. W., Tomassetti, S., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01668-1 · Cited by 79
Self-citationUsual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift?
Selman, M., Pardo, A., & Wells, A. U. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00475-1 · Cited by 77
Self-citationRenzoni, E. A., Poletti, V. E., & Mackintosh, J. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01961-9 · Cited by 76
Herrera, J. A., Dingle, L., Montero, M. A., Venkateswaran, R. V., Blaikley, J. F., Lawless, C., & Schwartz, M. A. (2022) · JCI Insight · doi:10.1172/jci.insight.156115 · Cited by 64
Cottin, V., Martínez, F. J., Smith, V. M., & Walsh, S. L. F. (2022) · European Respiratory Review · doi:10.1183/16000617.0003-2022 · Cited by 73
Self-citationChallenges for Clinical Drug Development in Pulmonary Fibrosis
White, E. S., Thomas, M. J., Stowasser, S., & Tetzlaff, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.823085 · Cited by 68
Self-citationLuteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases
Lv, J., Song, X., Luo, Z., Huang, D., Xiao, L., & Zou, K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1535555 · Cited by 71
“…in lung capacity, exacerbation of fi brosis as depicted on high-resolution computed tomography (HRCT) scans, decline in both symptomatology and quality of life for patients, and a propensity for early death (Travis et al., 2013; Wells et al., 2018; Cottin et al., 2019; Kolb and Va š áková, 2019).”
Olson, A. L., Patnaik, P., Hartmann, N., Bohn, R. L., Garry, E. M., & Wallace, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01786-8 · Cited by 63
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
Brown, K. K., Inoue, Y., Flaherty, K. R., Martínez, F. J., Cottin, V., Bonella, F., Cerri, S., Danoff, S. K., Jouneau, S., Goeldner, R.-G., et al. (2022) · Respirology · doi:10.1111/resp.14231 · Cited by 59
“In the placebo groups of these trials, the rate of decline in FVC and the risk of mortality were similar and a relative decline in FVC of >10% of the predicted value was associated with a more than three-fold increase in the risk of death over 52 weeks.(8) In addition to a decline in FVC, in subjects with fibrosing IL…”
BackgroundResultSelf-citationTakei, R., Brown, K. K., Yamano, Y., Kataoka, K., Yokoyama, T., Matsuda, T., Kimura, T., Suzuki, A., Furukawa, T., Fukuoka, J., et al. (2022) · Respirology · doi:10.1111/resp.14245 · Cited by 62
Self-citationOh, A. S., Lynch, D. A., Swigris, J. J., Baraghoshi, D., Dyer, D. S., Hale, V. A., Koelsch, T. L., Marrocchio, C., Parker, K. N., Teague, S. D., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202301-084oc · Cited by 62
Lung function trajectory of rheumatoid arthritis–associated interstitial lung disease
Chang, S. H., Lee, J. S., Ha, Y., Kim, M. U., Park, C. H., Lee, J. S., Kim, J., Chung, S. W., Pyo, J. Y., Lee, S. W., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead027 · Cited by 57
Cottin, V., Martinez, F. J., Jenkins, R. G., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Respiratory Research · doi:10.1186/s12931-022-01974-2 · Cited by 53
Self-citationThe Burden of Progressive-Fibrosing Interstitial Lung Diseases
Cottin, V., Teague, R., Nicholson, L. K., Langham, S., & Baldwin, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.799912 · Cited by 56
“Additionally, numerous studies significantly associated this increased risk of mortality with a decline in FVC (2, 21).”
BackgroundResultSelf-citationAllanore, Y., Vonk, M. C., Distler, O., Azuma, A., Mayes, M. D., Gahlemann, M., James, A., KOHLBRENNER, V. M., Alves, M., Khanna, D., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222564 · Cited by 53
“19 22 Although the SENSCIS and SENSCIS-ON trials were not designed to investigate the effects of combination therapy, we note that the smallest decline in FVC over 52 weeks of SENSCIS-ON occurred in patients receiving both nintedanib and mycophenolate, consistent with observations in the SENSCIS…”
Chiu, Y., Spierings, J., de Jong, P. A., Hoesein, F. A. A. M., Grutters, J. C., van Laar, J. M., & Voortman, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106579 · Cited by 55
Pérez, E. R. F., Crooks, J., Lynch, D. A., Humphries, S. M., Koelsch, T. L., Swigris, J. J., Solomon, J. J., Mohning, M. P., Groshong, S. D., & Fier, K. (2023) · Thorax · doi:10.1136/thorax-2022-219795 · Cited by 49
Walsh, S. L. F., Backer, J. D., Prosch, H., Langs, G., Calandriello, L., Cottin, V., Brown, K. K., Inoue, Y., Tzilas, V., & Estes, E. A. (2024) · European Respiratory Review · doi:10.1183/16000617.0055-2023 · Cited by 52
“PPF is associated with poor outcomes, including high mortality [55, 56 – 61] and a drawback of the current criteria is that patients must show significant progression, which is likely irreversible, before PPF is identified and treatment can be started.”
BackgroundSelf-citationThe Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
Behr, J., Salisbury, M. L., Walsh, S. L. F., Podolanczuk, A. J., Hariri, L. P., Hunninghake, G. M., Kolb, M. R. J., Ryerson, C. J., Cottin, V., Beasley, M. B., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0048pp · Cited by 49
Self-citationPredictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
Chen, X., Guo, J., Yu, D. H., Jie, B., & Zhou, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754851 · Cited by 47
“Progressive fibrosing interstitial lung disease (PF-ILD) is a terminology recently used to describe a subset of patients who have inexorable progression of pulmonary fibrosis despite treatment, and the underlying pathogenetic mechanism and clinical behaviors of which are similar to those of idiopathic pulmonary fibros…”
BackgroundInnate immune cell activation causes lung fibrosis in a humanized model of long COVID
Cui, L., Fang, Z., Souza, C. D., Lerbs, T., Guan, Y., Li, I., Charu, V., Chen, S.-Y., Weissman, I. L., & Wernig, G. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217199120 · Cited by 47
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger‐Christ, K., Pinto-Plata, V., Liesching, T. N., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02359-9 · Cited by 48
Tsitoura, E., Trachalaki, A., Vasarmidi, E., Mastrodemou, S., Margaritopoulos, G. A., Kokosi, M. A., Fanidis, D., Galaris, A., Aidinis, V., Renzoni, E. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645548 · Cited by 46
Self-citationEffects of nintedanib by inclusion criteria for progression of interstitial lung disease
Maher, T. M., Brown, K. K., Kreuter, M., Devaraj, A., Walsh, S. L. F., LANCASTER, L. H., Belloli, E. A., Padilla, M. L., Behr, J., Goeldner, R.-G., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04587-2020 · Cited by 49
Self-citationRaman, L., Stewart, I. D., Barratt, S. L., Chua, F., Chaudhuri, N., Crawshaw, A., Gibbons, M., Hogben, C., Hoyles, R. K., Kouranos, V., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00423-2022 · Cited by 41
Self-citationTsubouchi, K., Hamada, N., Tokunaga, S., Ichiki, K., Takata, S., Ishii, H., Kitasato, Y., Okamoto, M., Kawakami, S., Yatera, K., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001864 · Cited by 35
A Deep Learning-Based Radiomic Classifier for Usual Interstitial Pneumonia
Chung, J. H., Chelala, L., Pugashetti, J. V., Wang, J. M., Adegunsoye, A., Matyga, A. W., Keith, L. A., Ludwig, K. D., Zafari, S., Ghodrati, S., et al. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.10.012 · Cited by 41
Ren, X., Yang, T., Zhang, K.-K., Liu, Y., Wang, C., Wu, L., & Zhang, J. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123405 · Cited by 37
Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences
Cocconcelli, E., Balestro, E., Turato, G., Fiorentù, G., Bazzan, E., Biondini, D., Tinè, M., Bernardinello, N., Pezzuto, F., Baraldo, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437767 · Cited by 36
“…course of IPF [INPULSIS trial (2)] and other ILDs [INBUILD trial (3)] suggests that progressive ILDs other than IPF not only have clinical courses similar to IPF but also responded to nintedanib treatment by signi fi cantly decreasing FVC decay independently of the fi brotic pattern on HRCT (3 – 5).”
BackgroundDecline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis
Maher, T. M., Stowasser, S., Voß, F., Bendstrup, E. M., Kreuter, M., Martínez, F. J., Sime, P. J., & Stock, C. (2023) · Respirology · doi:10.1111/resp.14579 · Cited by 35
Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Strykowski, R. K., & Adegunsoye, A. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.010 · Cited by 36
Liang, M., Matteson, E. L., Abril, A., & Distler, J. H. W. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221074457 · Cited by 34
Physical Health and Psychosocial Considerations During the Coronavirus Disease 2019 Outbreak
Giacalone, A., Rocco, G., & Ruberti, E. (2020) · Psychosomatics · doi:10.1016/j.psym.2020.07.005 · Cited by 37
“Progressive, fibrotic irreversible interstitial lung disease is characterzsed by declining lung function, increasing extent of fibrosis on computed tomography (CT), worsening symptoms and quality of life, and early mortality.(5)”
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
Gibson, C. D., Kugler, M. C., Deshwal, H., Munger, J. S., & Condos, R. (2020) · Lung · doi:10.1007/s00408-020-00370-1 · Cited by 32
Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
Jehn, L. B., Costabel, U., Boerner, E. B., Wälscher, J., Theegarten, D., Taube, C., & Bonella, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031173 · Cited by 31
Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease
Watase, M., Mochimaru, T., Kawase, H., Shinohara, H., Sagawa, S., Ikeda, T., Yagi, S., Yamamura, H., Matsuyama, E., Kaji, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283288 · Cited by 30
“Mortality rates and lung function decline were found to be similar between patients with PF-ILD and those with IPF [1].”
BackgroundResultLópez-Matencio, J. M. S., Gómez, M., Vicente‐Rabaneda, E. F., González-Gay, M. Á., Ancochea, J., & Castañeda, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080819 · Cited by 31
“Interstitial lung diseases (ILD) are a heterogeneous group of pulmonary disorders characterized by varying degrees of inflammation and fibrosis resulting in the loss of alveolar function and impairment of gas exchange [1].”
BackgroundInfluentialSwigris, J. J., Bushnell, D. M., Rohr, K., Mueller, H., Baldwin, M., & Inoue, Y. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001167 · Cited by 30
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001580 · Cited by 28
“1 6–8 Nintedanib is approved for both IPF and PPF based on similar clinical outcomes and consistent effects in both diseases.”
BackgroundSelf-citationNambiar, A. M., Walker, C. M., & Sparks, J. A. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211039771 · Cited by 28
Трушенко, Н. В., Suvorova, O., Pershina, E. S., Nekludova, G. V., Chikina, S. Y., Levina, I. A., Chernyaev, A. L., Samsonova, M. V., Tyurin, I. E., Mustafina, M., et al. (2023) · Life · doi:10.3390/life13020467 · Cited by 26
“The presence of a typical usual interstitial pneumonia (UIP) pattern on HRCT had a significant impact on the prognosis in patients with progressive p lmonary fibrosis [18].”
BackgroundResultInfluentialAvdeev, S. N., Chikina, S. Y., Tyurin, I. E., Belevskiy, А. S., Terpigorev, S. A., Ananyeva, L. P., VIZEL, A. A., Болдина, М. В., Демко, И. В., Викторович, Л. И., et al. (2021) · PULMONOLOGIYA · doi:10.18093/0869-0189-2021-31-4-505-510 · Cited by 24
SFTPB in serum extracellular vesicles as a biomarker of progressive pulmonary fibrosis
Enomoto, T., Shirai, Y., Takeda, Y., Edahiro, R., Shichino, S., Nakayama, M., Takahashi-Itoh, M., Noda, Y., Adachi, Y., Kawasaki, T., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.177937 · Cited by 25
“Among ILDs, idiopathic pulmonary fibrosis (IPF) shows a typical progressive phenotype, while some patients with non-IPF-ILDs may also exhibit deteriorating lung function and early death (3, 4).”
BackgroundCottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.005 · Cited by 27
Self-citationFrom pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump
Selman, M., & Pardo, A. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00310.2021 · Cited by 23
Koslow, M., Baraghoshi, D., Swigris, J. J., Brown, K. M., Pérez, E. R. F., Huie, T. J., Keith, R. C., Mohning, M. P., Solomon, J. J., Yunt, Z. X., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202503-0535oc · Cited by 24
Self-citationDiagnosis and Management of Fibrotic Interstitial Lung Diseases
Collins, B. F., & Luppi, F. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.008 · Cited by 22
Liu, F., Yao, Y., Guo, C., Dai, P., Huang, J., Peng, P., Wang, M., Dawa, Z., Zhu, C., & Lin, C. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155755 · Cited by 22
Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases
Castelino, F. V., & Moua, T. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11253 · Cited by 22
Novedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva
Molina‐Molina, M., Buendía-Roldán, I., Castillo, D., Caro, F. M., Valenzuela, C., & Selman, M. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.12.006 · Cited by 25
Joannes, A., Voisin, T., Morzadec, C., Letellier, A., Llamas‐Gutierrez, F., Chiforeanu, D. C., Naourès, C. L., Guillot, S., Latour, B. R. D., Rouzé, S., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102267 · Cited by 22
Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline
Nagy, A., Nagy, T., Kolonics-Farkas, A. M., Eszes, N., Vincze, K., Bárczi, E., Tárnoki, Á. D., Tárnoki, D. L., Nagy, G. M., Kiss, E. V., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.778649 · Cited by 22
“PF-ILD) trial included DLCO of at least 30% and less than 80% predicted (Brown et al., 2020; Flaherty et al., 2019).”
BackgroundMeta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Bonella, F., Cottin, V., Valenzuela, C., Wijsenbeek, M. S., Voß, F., Rohr, K. B., Stowasser, S., & Maher, T. M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02145-x · Cited by 21
“However, of note, the absolute rate of FVC decline observed in patients with IPF was similar to that observed in patients with other progressive fibrosing ILDs [14].”
ResultSelf-citationCottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100948 · Cited by 25
Self-citationThe fibroblast activation protein alpha as a biomarker of pulmonary fibrosis
Lavis, P., Garabet, A., Cardozo, A. K., & Bondue, B. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1393778 · Cited by 20
A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis
Wang, J. M., Adegunsoye, A., Pugashetti, J. V., Lee, C. T., Murray, S., Mohan, N., Nazemi, N., Kang, E., Chelala, L., Kazerooni, E. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202501-0208oc · Cited by 21
Clinical characteristics and prognostic factors of fibrotic nonspecific interstitial pneumonia
Cho, H. K., Chung, M. P., Lee, K. S., Chung, M. J., Han, J., Kwon, O. J., & Yoo, H. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221089468 · Cited by 20
Progressive Pulmonary Fibrosis: Where Are We Now?
Kang, H. K., & Song, J. W. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0119 · Cited by 21
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
Chang, S. H., Paudel, M. L., McDermott, G. C., Zhang, Q., Fukui, S., Kim, M. U., Ha, Y., Lee, J. S., Lee, S. W., Park, C. H., et al. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152729 · Cited by 23
Birring, S. S., Bushnell, D. M., Baldwin, M., Mueller, H., Male, N., Rohr, K. B., & Inoue, Y. (2021) · European Respiratory Journal · doi:10.1183/13993003.01790-2021 · Cited by 19
Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study
Guler, S. A., Machahua, C., Geiser, T., Kocher, G. J., Marti, T. M., Tan, B., Trappetti, V., Ryerson, C. J., & Funke-Chambour, M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02076-9 · Cited by 20
Kreuter, M., Bendstrup, E. M., Jouneau, S., Maher, T. M., Inoue, Y., Miede, C., Lievens, D., & Crestani, B. (2023) · Respiratory Research · doi:10.1186/s12931-023-02371-z · Cited by 19
Usefulness of CT Quantification-Based Assessment in Defining Progressive Pulmonary Fibrosis
Ahn, Y., Kim, H. C., Lee, J. K., Noh, H. N., Choe, J., Seo, J. B., & Lee, S. M. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.05.005 · Cited by 19
Insights into the Pathogenesis of Pulmonary Fibrosis from Genetic Diseases
Wang, J. Y., & Young, L. R. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0557tr · Cited by 20
Chiu, Y., Koops, M. F. M., Voortman, M., van Es, H. W., Langezaal, L. C. M., Welsing, P. M. J., Jamnitski, A., Wind, A. E., van Laar, J. M., Grutters, J. C., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1106560 · Cited by 22
“Identification of patients with PPF is crucial for clinical practice, as these patients have a poor prognosis and may benefit from antifibrotic drugs similar to patients with idiopathic pulmonary fibrosis (IPF) in randomized controlled trials (8, 9); however, the definition of PPF criteria differ between studies.”
BackgroundInfluentialAronson, K. I., & Suzuki, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745908 · Cited by 20
Chen, Y., Lee, T.-J., Hsieh, H.-J., Hsieh, S., Wang, H., Chang, Y., Yu, C., & Chien, J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02562-w · Cited by 18
Sadeleer, L. D., Goos, T., Yserbyt, J., & Wuyts, W. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061722 · Cited by 20
“Although all patients included in the INBUILD trial were progressive at inclusion (as this was needed for inclusion), only 40% and 60% of the placebo cases had a >10% and 5%‒10% FVC decline, respectively, throughout the first 52 weeks of the trial [23].”
BackgroundResultImpact of Palliative Care in End-of-Life of Fibrotic Interstitial Lung Disease Patients
Chai, G. T., Neo, H. Y., Abisheganaden, J. A., & Hum, A. Y. M. (2022) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221083575 · Cited by 19
“This so-called “progressive fibrotic phenotype” often follows similar lung function decline and mortality when compared against IPF patients.(37) This study is not without limitations as it is a single center study with small numbers and prone to selection biases, resulting in significant differences in comorbidity bu…”
BackgroundProgressive Fibrosing Interstitial Lung Diseases: A Current Perspective
Albera, C., Verri, G., Sciarrone, F., Sitia, E., Mangiapia, M., & Solidoro, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091237 · Cited by 17
Moda, M., Suga, M., Kasai, S., Okochi, Y., Yoshimura, N., Fukata, M., & Tokuda, H. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.05.037 · Cited by 16
Salonen, J., Vähänikkilä, H., Purokivi, M., & Kaarteenaho, R. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242860 · Cited by 17
Interstitial Lung Disease Associated with Systemic Sclerosis
Mismetti, V., Si-Mohamed, S. A., & Cottin, V. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786698 · Cited by 19
Self-citationJang, J. H., Choe, E. J., Jung, S. Y., Ko, J., Kim, D.-W., & Lee, J. H. (2024) · Medicine · doi:10.1097/md.0000000000038226 · Cited by 17
“[5,9,10] Hence, we conducted this study to assess the prevalence, risk factors and prognosis of PPF among patients with ILD other than IPF in real-world practice.”
MethodJin, D., An, X., Zhang, Y., Zhao, S., Duan, L., Duan, Y., Lian, F., & Tong, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.602218 · Cited by 20
Takei, R., Matsuda, T., Fukihara, J., Sasano, H., Yamano, Y., Yokoyama, T., Kataoka, K., Kimura, T., Suzuki, A., Furukawa, T., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1067149 · Cited by 15
The detrimental effect of quantity of smoking on survival in progressive fibrosing ILD
Platenburg, M. G. J. P., van der Vis, J. J., Kazemier, K. M., Grutters, J. C., & van Moorsel, C. H. M. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106760 · Cited by 15
Ushio, Y., Wakiya, R., Kameda, T., Nakashima, S., Shimada, H., Miyagi, T., Sugihara, K., Mino, R., Mizusaki, M., Chujo, K., et al. (2024) · BMC Rheumatology · doi:10.1186/s41927-024-00400-y · Cited by 14
“The clinical course of PF-ILD, which progresses despite appropriate treatment, is known to have a poor prognosis, similar to that of untreated idiopathic pulmonary fibrosis (IPF) [2].”
BackgroundYang, X., Lin, G., Chen, Y., Lei, X., Ou, Y., Yan, Y., Wu, R., Yang, J., Luo, Y., Zhao, L., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.4c00798 · Cited by 15
Metadata
- Authors
- Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., & Wells, A. U.
- Affiliations
- National Jewish Health (US)
- Imperial College London (GB)
- University of Alabama at Birmingham (US)
- Medizinische Hochschule Hannover (DE)
- Boehringer Ingelheim (Germany) (DE)
- Lyon 1 Université (FR)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Corresponding author
- Brown, Kevin K.
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-03-26
- Volume
- 55
- Issue
- 6
- Pages
- 2000085
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC7315005
- OpenAlex
- W3013021754
- Semantic Scholar
- eeb975721a6bad50451a09c9b2ffa308b44a51aa
- Cited by
- 293
- References
- 35
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 46 · 2023: 41 · 2022: 66 · 2021: 62 · 2020: 12
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- progressive fibrosing interstitial lung disease, idiopathic pulmonary fibrosis, natural history (disease), forced vital capacity decline, mortality, ILD progression, INBUILD trial, INPULSIS trials
- MeSH terms
- Aged, Female, Humans, Indoles, Male, Middle Aged, Vital Capacity, Lung Diseases, Interstitial, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.